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SUMMARY
Introduction—The phosphotidylinositol-3 kinase (PI3K)/serine–threonine kinase (AKT)/
mammalian target of rapamycin (mTOR) signaling pathway is frequently altered in head and neck 
squamous cell cancer (HNSCC). PX-866 is an oral, irreversible, pan-isoform inhibitor of PI3K. 
Preclinical models revealed synergy with docetaxel and a phase 1 trial demonstrated tolerability of 
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this combination. This randomized phase 2 study evaluated PX-866 combined with docetaxel in 
patients with advanced, refractory HNSCC.
Methods—Patients with locally advanced, recurrent or metastatic HNSCC who had received at 
least one and no more than two prior systemic treatment regimens were randomized (1:1) to a 
combination of docetaxel (75 mg/m2 IV every 21 days) with or without PX-866 (8 mg PO daily; 
Arms A and B, respectively). The primary endpoint was progression free survival (PFS). 
Secondary endpoints included objective response rate (RR), overall survival (OS), toxicity, and 
correlation of biomarker analyses with efficacy outcomes.
Results—85 patients were enrolled. There was a non-significant improvement in response rate in 
the combination arm (14% vs. 5%; P = 0.13). Median PFS was 92 days in Arm A and 82 days in 
Arm B (P = 0.42). There was no difference in OS between the two arms (263 vs. 195 days; P = 
0.62). Grade 3 or higher adverse events were infrequent, but more common in the combination 
arm with respect to diarrhea (17% vs. 2%), nausea (7% vs. 0%), and febrile neutropenia (21% vs. 
5%); grade 3 or higher anemia was more frequent in arm B (7% vs. 27%). PIK3CA mutations or 
PTEN loss were infrequently observed.
Conclusion—The addition of PX-866 to docetaxel did not improve PFS, RR, or OS in patients 
with advanced, refractory HNSCC without molecular pre-selection.
Keywords
PIK3CA; PI3K; Docetaxel; Head and neck squamous cell cancer
Introduction
The phosphotidylinositol-3 kinase (PI3K)/serine–threonine kinase (AKT)/mammalian target 
of rapamycin (mTOR) signaling pathway is frequently altered in human cancers, leading to 
cell proliferation, enhanced expression of survival genes and decreased expression of pro-
apoptotic factors [1]. PI3K is an intracellular kinase comprised of the p110α, p110β, or 
p110δ catalytic subunits, and a p85 regulatory subunit; mutations to p110α and p85 are 
oncogenic [2,3]. Activating mutations to PIK3CA, the gene encoding the p110α catalytic 
subunit of PI3K, are found in several tumor types, including glioblastoma (27%), breast 
(18%), colorectal (16% of non-hypermutated tumors), cervical (33%), head and neck 
squamous cell cancer (HNSCC; 6–8%), and non-small cell lung cancer (NSCLC; 2–6%) 
[2,4–9]. Increased PIK3CA copy numbers are seen in prostate cancer (28%), squamous 
histology NSCLC (33%), and HNSCC (45%) [10–12]. The phosphatase and tensin homolog 
(PTEN) tumor suppressor gene, which inhibits PI3K signaling, may be lost via deletion 
(25% of melanoma, breast, and prostate cancers), mutation, or epigenetic suppression [13–
16]. Lastly, upstream growth factor receptors that activate PI3K signaling, such as epidermal 
growth factor receptor (EGFR) and insulin-like growth factor receptor, are often over-
expressed in cancer [17,18].
PX-866 is a novel oral, pan-isoform inhibitor of PI3K [19]. In a phase 1 study, both PX-866 
and docetaxel were given at their single agent maximal tolerated doses in patients with 
advanced cancers [20]. The majority of adverse events (AE) were gastrointestinal and grade 
≤2 similar to the single agent PX-866 trial [21]. Best response per Response Evaluation 
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Criteria in Solid Tumors (RECIST) 1.1 [22] was stable disease in over 50% of evaluable 
patients at Week 6. Consistent with other studies investigating PI3K inhibitors, PIK3CA 
mutations were associated with longer duration of stable disease, but this was not 
statistically significant [21,23].
PX-866 had substantial antitumor efficacy in preclinical studies using a HNSCC patient 
derived xenograft (PDX) model that occurred both in cases with and without a PIK3CA 
activating genetic events [24]; in this same model an additive/synergistic effect was observed 
in vivo with docetaxel (unpublished data). Docetaxel has been shown to be an active agent in 
relapsed/metastatic (R/M) HNSCC in weekly and every 3 week regimens [25,26], is 
considered an appropriate second/third line therapy by the National Comprehensive Cancer 
Network (NCCN) guidelines, and has a toxicity profile that does not overlap with that of 
PX-866.
Therefore, we conducted an open-label, randomized, phase 2 trial comparing docetaxel 
alone versus docetaxel plus PX-866 without the possibility of cross-over in patients with 
R/M HNSCC in the second or third-line setting.
Patient and methods
Eligibility criteria
Subjects had R/M HNSCC for which they had received 1–2 prior systemic therapies, 
including up to one platinum-based chemotherapy regimen. Other key inclusion criteria 
were age ≥18 years, measurable disease by RECIST 1.1 criteria [22], ECOG performance 
status 0–1, life expectancy ≥3 months, and adequate hematologic, hepatic and renal function. 
Treatment with any systemic anti-cancer or radiation therapy was not allowed within 4 
weeks of study drug dosing. Patients with adequately treated and stable brain metastases 
were eligible.
Salient exclusion criteria included known HIV infection; medical, social or psychological 
factors affecting safety or compliance; grade ≥2 neuropathy; history of hypersensitivity to 
docetaxel or other drugs formulated with polysorbate; pregnant/breastfeeding; prior 
docetaxel for R/M HNSCC or within 6 months of enrollment in the curative setting; or any 
prior treatment with a PI3K inhibitor. Each center’s institutional review board granted 
approval and written informed consent was mandatory.
Treatment and efficacy assessments
Patients were randomized to docetaxel 75 mg/m2 IV once every 21 days with or without 
PX-866 8 mg by mouth daily in a 1:1 fashion without stratification factors. Colony 
stimulating factors and anti-emetics were permitted in any cycle according to institutional 
guidelines. All patients received dexamethasone 8 mg orally twice daily for 3 days starting 
the day before docetaxel administration. Patients were evaluated for progression every 2 
cycles. Patients continued therapy as long as they had stable disease or better per RECIST 
1.1 criteria and lacked unacceptable toxicity or withdrawal of consent. Patients in the 
combination arm were allowed to continue PX-866 alone after discontinuation of docetaxel.
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Safety assessments included vital signs, laboratory assessments and physical exams. 
Adverse events (AEs) were assessed using the NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.02. Up to two dose reductions were allowed for 
docetaxel (60 and 45 mg/m2) and three dose reductions for PX-866 (6, 4 and 2 mg per day). 
Subjects requiring additional dose reductions of PX-866 were removed from study. Study 
drugs were discontinued if treatment needed to be delayed by more than two weeks.
Biomarker measurements
Optional archival tumor specimens were centrally evaluated for PIK3CA and KRAS 
mutations, p16 and PTEN expression by immunohistochemistry (IHC) using a standard 
clinical assay or as previously described [21,27].
Statistics
The primary endpoint of this study was progression-free survival (PFS) and secondary 
endpoints were objective response rate (ORR), incidence and severity of AEs, overall 
survival (OS) and exploratory endpoints of biomarker correlations with efficacy. A docetaxel 
alone control of median PFS of 3 months was assumed for the HNSCC study population. 
With a 1-sided 0.20 false positive error rate, a projected 1-year enrollment period with an 
additional 0.5 years of follow-up prior to analysis and a control over experimental hazard 
ratio of 1.5, a total of 80 patients were required for the log-rank test with 0.80 power to 
detect a statistically significant benefit in terms of lengthening PFS of the combination arm 
of docetaxel plus PX-866 versus docetaxel alone.
Results
Patient characteristics
Eighty-five patients were enrolled between November 2011 and June 2013. 42 and 43 
patients were randomized to the PX-866 plus docetaxel (arm A) and docetaxel alone group 
(arm B), respectively. Baseline characteristics were well balanced between the two arms. 
The groups were similar with respect to numbers of prior systemic therapies and median 
time since diagnosis Table 1.
Treatment delivered
In arm A, 42 patients (100%) received at least one dose of PX-866 and/or docetaxel, while 
41 patients (95%) in arm B received at least one dose of docetaxel. The median number of 
docetaxel cycles administered was 3.5 (range, 1–13) and 4 (range, 1–12) in arms A and B, 
respectively. The dose intensity of docetaxel was equivalent, with 70 mg/m2/cycle and 72 
mg/m2/cycle in arms A and B, respectively. Thirty-four patients (81%) experienced a total of 
97 dose interruptions or modifications of PX-866, with 61 (63%) of disruptions due to 
adverse events. The most common reason for PX-866 dose disruptions was diarrhea, which 
is consistent with the single agent toxicity of this agent. A total of 56 patients (29 in arm A 
and 27 in arm B) were taken off study due to disease progression.
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Sixty-eight (80%) patients were evaluable for response as measured by RECIST 1.1 (35 in 
Arm A, 33 in Arm B). There were no complete responses (CR) in either arm. There were 6 
(14%) and 2 (5%) confirmed partial responses (PR) in arms A and B, respectively, a 
difference that was not statistically significant (P = 0.13). There was one additional 
unconfirmed PR in each arm. There were 9 (21%) and 8 (19%) patients receiving 7 or more 
cycles in arms A and B, respectively (P = 0.79). There were no differences in the disease 
control rates (CR + PR + stable disease [SD]) after 2 cycles that were 57% and 54% for 
arms A and B, respectively (Table 2). Median PFS was 92 days (95% CI 46–119) for arm A 
and 82 days (95% CI 47–96) for arm B (P = 0.42, Fig. 1). The PFS estimates at 3 months 
were 50% (95% CI 33–65%) for arm A and 38% (95% CI 23–53%) for arm B, respectively. 
The hazard ratio for PFS was 0.95 (95% CI 0.57–1.58). Median OS was 263 days in arm A 
(95% CI 125–383) and 195 days in arm B (95% CI 121–NR; P = 0.62, Fig. 2).
Human papillomavirus (HPV) and treatment efficacy
HPV testing was conducted centrally. Of the 49 patients with available tissue for analysis, 25 
patients (51%) were HPV positive and 24 (49%) were HPV negative (Table 3). There were 
15 HPV positive patients randomized to arm A, versus 10 that were allocated to arm B, an 
imbalance that was not significant (P = 0.24). Out of the 17 patients that received therapy for 
7 or more cycles, 7 (41%) were HPV positive, 4 (24%) were HPV negative, and 6 (35%) had 
an unknown status. Out of the 8 patients that had a confirmed PR, 4 (50%) were HPV 
positive, 1 (13%) was HPV negative, and 3 (37%) had an unknown status.
Genomics
Of the 49 patients whose archival tumors were analyzed 4 (8%) had PIK3CA exon 9 
mutations (3 G1633A, 1 A1634G; 3 in arm A and 1 in arm B; 3 HPV positive, 1 HPV 
negative) while none had KRAS mutations. PTEN expression was reduced or absent in 3 
patients (2 in arm A, 1 in arm B; 2 HPV positive, 1 HPV negative). PIK3CA mutation, and 
PTEN IHC could not be correlated with PFS, ORR, or OS due to their rarity.
Safety and tolerability
Eighty-three enrolled patients received at least one treatment on protocol and were 
considered evaluable for safety (all 42 in arm A and 41 in arm B). In both arms most adverse 
events were ≤2 (Table 4). There were more treatment related adverse events in arm A (all 
grade, 281; grade 3–5, 85) compared to arm B (all grade, 186; grade 3–4, 43). Specifically in 
arm A there was more diarrhea (64% vs. 22%), vomiting (57% vs. 15%), nausea (50% vs. 
29%), electrolyte deficits (hypomagnesemia and hyponatremia both 19% in arm A and 7% 
in arm B), rash (14% vs. 0%), and ALT/AST elevation (17% vs. 0%). There were similar 
rates of infections (pneumonia and candidiasis at 17% and 12% in both groups, respectively) 
between both arms. In terms of hematological toxicity, febrile neutropenia was more 
common in arm A (21% vs.5%), but with more reported anemia in arm B (14% vs. 29%). 
Six patients in arm A died during the study (1 related to toxicity; pneumonia) while 2 
patients in arm B passed away during treatment. Three patients in arm A withdrew due to 
AEs while 2 patients in arm B were taken off study due to toxicity.
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This manuscript reports on a prospective, randomized study of docetaxel plus/minus a small 
molecule inhibitor targeted against PI3K in relapsed or metastatic HNSCC patients. 
Although the combination failed to improve outcomes compared to docetaxel alone, this is 
one of the first prospective trials in the HPV era, and it showed a higher proportion of HPV 
positive patients over HPV negative than expected, which has profound implications in trial 
design. It also assessed a PI3K inhibitor targeting the protein product of PIK3CA, the gene 
with the highest rate of activating mutations in HNSCC.
The primary question of this trial was answered unequivocally; the addition of PX-866 to 
docetaxel failed to improve PFS, ORR, or OS in patients with R/M HNSCC. The higher 
observed response rate was not statistically significant (P = 0.13), though this may be a 
reflection of a small sample size. However the PFS was only 10 days longer in the 
combination arm, and OS estimates were non-significant. It is possible that the lack of 
clinical benefit resulted from lack of molecular pre-selection in this study, as very few 
tumors harbored genetic alterations (PIK3CA mutations, PTEN loss) thought to predict 
sensitivity to PI3K inhibitors.
While it has been difficult to identify predictive biomarkers across all tumor types for this 
class of drugs, preclinical and clinical data suggest that PI3K pathway activation may 
correlate with sensitivity to PI3K inhibitors [24,28–30]. PX-866 has been efficacious in a 
HNSCC PDX in cases with PIK3CA activating mutations or gene amplification, although 
activity was also seen in cases without any such genetic events [24]. The data from the 
PX-866 clinical experience as well for other PI3K inhibitors suggest that currently 
identifiable pathway alterations are not always sufficient to predict efficacy [31].
It is interesting to note that in this dataset of R/M HNSCC patients, 51% of those where 
HPV status could be tested were positive. We did not identify significant differences in 
treatment-related efficacy (either by response rate or by patients receiving more than 6 
cycles, a surrogate for benefit) between HPV positive and HPV negative patients, but this 
trial was not powered to address sub-group analyses.
While the addition of PX-866 to docetaxel was reasonably well tolerated, toxicity appeared 
to be more pronounced in the combination arm. This was particularly evident in the 
incidence of GI toxicities (nausea, vomiting, and diarrhea), leading to electrolyte 
imbalances. The data of this trial pertaining hematological toxicity is less consistent, since 
there was more neutropenia but less anemia in the combination arm compared to docetaxel 
alone; we do not have a readily available explanation for this dichotomy. Many of AEs are 
consistent with other phase 1/2 studies evaluating PI3K inhibitors including our own phase 1 
study [20], and the previously reported “twin” study in non-small cell lung cancer [32]. The 
side effect profile was remarkably similar in our trial in HNSCC compared to the NSCLC 
study, including the toxicity imbalances with the exception of neutropenia. To date, rash, 
hyperglycemia, and transaminase elevations appear to be class effects of PI3K/AKT/mTOR 
inhibition, although gastrointestinal side effects have been reported in studies as well [33]. 
However, in addition to PX-866 other PI3K inhibitors such as XL147 have reported a 
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relative lack of glycemic toxicity [31]. Interestingly, despite more frequent adverse events in 
the combination arm, the proportion of patients being taken off study due to toxicity was 
similar between arms suggesting that the toxicity was manageable; similarly, the docetaxel 
dose intensity was similar between arms, indicating that combination therapy did not lead to 
less intense standard therapy administration.
In summary, the addition of PX-866 to docetaxel did not improve clinical outcomes over 
docetaxel alone in a molecularly unselected population of R/M HNSCC patients. Further 
investigations with PI3K inhibitors in HNSCC should focus on appropriate biomarker or 
histology selection to maximize the chances of clinical benefit. While PIK3CA activating 
genetic events may predict sensitivity to this class of drugs, a solid link has been elusive, 
challenging the hypothesis that PIK3CA mutations alone support oncogenesis and tumor 
growth in contrast to other oncogenic mutations. Further exploration is needed to better 
define molecularly those patients most likely to derive a benefit from such agents, since it is 
likely that associated genetic events may help predict their utility.
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Kaplan–Meier curves for progression free survival (days).
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Kaplan–Meier curves for overall survival (days).
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Table 1
Patient characteristics.
PX-866 + docetaxel (n = 42) Docetaxel (n = 43)
Median age (range) 62 (36–81) 60 (40–82)
Sex
Female 4 (10%) 7 (16%)
Male 38 (90%) 36 (84%)
Ethnicity
Caucasian 39 (93%) 37 (86%)
African American 3 (7%) 5 (12%)
Other 0 (0%) 1 (2%)
ECOG
0 12 (29%) 8 (19%)
1 30 (71%) 35 (81%)
Stage at diagnosis I/II/III/IV (%) 2/5/14/79 5/9/16/70
Stage at baseline III/IV (%) 0 (0%)/42 (100%) 1 (2%)/42 (98%)
Prior anti-cancer therapy 42 (100%) 43 (100%)
Systemic therapy 27 (64%) 22 (51%)
Radiotherapy 10 (24%) 10 (23%)
Systemic/radiotherapy 35 (83%) 37 (86%)
Number of prior systemic therapies mean/range 1.7 (1–4) 1.7 (1–4)
Median time since diagnosis, months 18.0 20.2
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Table 2
Response rate.a
PX-866 + Docetaxel (n = 42) Docetaxel (n = 43)
Complete response 0 0
Partial response 6 (14%) 2 (5%)
Stable disease 18 (43%) 21 (49%)
Progressive disease 11 (26%) 10 (23%)
Not evaluable 7 (17%) 10 (23%)
Disease control rate (CR/PR/SD) 24 (57%) 23 (54%)
a
Response rate represent best overall response rate (investigator).
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Table 3
Treatment distribution by HPV status.
PX-866 + docetaxel (n = 42) Docetaxel (n = 43)
HPV positive 15 (36%) 10 (23%)
PIK3CA mutation 3 (8%) 0 (0%)
7 or more cycles 6 (14%) 1 (2%)
Partial response 3 (7%) 1 (2%)
HPV negative 12 (28%) 12 (28%)
PIK3CA mutation 0 (0%) 1 (2%)
7 or more cycles 1 (2%) 3 (7%)
Partial response 1 (2%) 0 (0%)
Not available 15 (36%) 21 (49%)
PIK3CA mutation 0 (0%) 0 (0%)
7 or more cycles 2 (5%) 4 (9%)
Partial response 2 (5%) 1 (2%)





















Jimeno et al. Page 15
Table 4
Adverse events occurring in 10% or more of one of the arms.
Adverse event PX-866 + Docetaxel (n = 42) Docetaxel alone (n = 41)
All grades Grade ≥3 All grades Grade ≥3
Hematological
Anemia 6 (14%) 3 (7%) 12 (29%) 11 (27%)
Neutropenia 26 (62%) 26 (62%) 16 (39%) 15 (37%)
Thrombocytopenia 0 (0%) 0 (0%) 1 (2%) 0 (0%)
Febrile neutropenia 9 (21%) 9 (21%) 2 (5%) 2 (5%)
Non-hematological
Abdominal pain 7 (17%) 2 (5%) 1 (2%) 0 (0%)
Diarrhea 27 (64%) 7 (17%) 9 (22%) 1 (2%)
Constipation 5 (12%) 0 (0%) 12 (29%) 0 (0%)
Nausea 21 (50%) 3 (7%) 12 (29%) 0 (0%)
Stomatitis 7 (17%) 0 (0%) 4 (10%) 2 (5%)
Vomiting 24 (57%) 2 (4%) 6 (15%) 0 (0%)
Fatigue 22 (52%) 3 (7%) 20 (49%) 4 (10%)
Peripheral edema 7 (17%) 0 (0%) 3 (7%) 0 (0%)
Candidiasis 5 (12%) 0 (0%) 5 (12%) 1 (2%)
Pneumonia 7 (17%) 5 (12%) 7 (17%) 4 (10%)
Weight loss 6 (14%) 0 (0%) 3 (7%) 1 (2%)
Dehydration 14 (33%) 0 (0%) 7 (17%) 0 (0%)
Hypokalemia 6 (14%) 3 (7%) 2 (5%) 0 (0%)
Hypomagnesemia 8 (19%) 0 (0%) 3 (7%) 1 (2%)
Hyponatremia 8 (19%) 6 (14%) 3 (7%) 3 (7%)
Transaminitis 7 (17%) 2 (5%) 0 (0%) 0 (0%)
Headache 6 (14%) 1 (2%) 3 (7%) 0 (0%)
Insomnia 9 (21%) 0 (0%) 2 (5%) 0 (0%)
Cough 9 (21%) 0 (0%) 7 (17%) 0 (0%)
Dyspnea 6 (14%) 1 (2%) 10 (24%) 4 (10%)
Oropharynx pain 2 (5%) 0 (0%) 5 (12%) 0 (0%)
Alopecia 6 (14%) 0 (0%) 4 (10%) 0 (0%)
Rash 6 (14%) 0 (0%) 1 (2%) 0 (0%)
Hypotension 5 (12%) 2 (5%) 6 (15%) 0 (0%)
Pyrexia 6 (14%) 0 (0%) 6 (15%) 0 (0%)
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